SCHEMBL1962294

SCHEMBL1962294

COC(=O)c1ccc(C(=CC2CCCC2)c2cc3cccnc3n2S(=O)(=O)c2ccccc2)c(F)c1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.37
SLC40A1 Q9NP59 1/20 0.37
ALOX15 P16050 1/20 0.35
HTT P42858 1/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
LMNA P02545 2/20 0.35
PTGDR2 Q9Y5Y4 3/20 0.34
PDE4B Q07343 5/20 0.34
PDE4D Q08499 1/20 0.34
CNR2 P34972 1/20 0.34
HSD17B10 Q99714 1/20 0.33
KDM4E B2RXH2 1/20 0.33
KMT2A Q03164 1/20 0.33
GAA P10253 1/20 0.33
CCKAR P32238 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1962291 1.00 GCK (0.37) GCKSLC40A1ALOX15HTTALDH1A1
SCHEMBL1960944 0.94 GCK (0.38) GCKSLC40A1ALDH1A1MAPTLMNA
SCHEMBL1960945 0.94 GCK (0.38) GCKSLC40A1ALDH1A1MAPTLMNA
SCHEMBL1959817 0.90 GCK (0.40) GCKSLC40A1ALOX15HTTALDH1A1
SCHEMBL1959819 0.90 GCK (0.40) GCKSLC40A1ALOX15HTTALDH1A1
SCHEMBL1963059 0.84 ALDH1A1 (0.35) GCKALDH1A1LMNAHSD17B10KDM4E
SCHEMBL1963061 0.84 ALDH1A1 (0.35) GCKALDH1A1LMNAHSD17B10KDM4E
SCHEMBL1962397 0.83 ALDH1A1 (0.34) GCKALDH1A1MAPTLMNAHSD17B10
SCHEMBL1962395 0.83 ALDH1A1 (0.34) GCKALDH1A1MAPTLMNAHSD17B10
SCHEMBL1959234 0.82 ALDH1A1 (0.40) GCKHTTALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 GCK 1/4885SLC40A1 1501/4885ALOX15 2448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.